Literature DB >> 31295673

Characteristics of hypersensitivity pneumonitis diagnosed by interstitial and occupational lung disease multi-disciplinary team consensus.

Gareth I Walters1, Justin M Mokhlis2, Vicky C Moore2, Alastair S Robertson3, Geraldine A Burge2, Parminder S Bhomra2, P Sherwood Burge3.   

Abstract

INTRODUCTION: The causes of hypersensitivity pneumonitis (HP) in the UK are changing as working practices evolve, and metalworking fluid (MWF) is now a frequently reported causative exposure. We aimed to review and describe all cases of HP from our UK regional service, with respect to the causative exposure and diagnostic characteristics.
METHODS: In a retrospective, cross-sectional study, we collected patient data for all 206 cases of HP diagnosed within our UK-based regional NHS interstitial and occupational lung disease service, 2002-17. This included demographics, environmental and occupational exposures, clinical features, and diagnostic tests (CT imaging, bronchiolo-alveolar cell count, lung function, histology). We grouped the data by cause (occupational, non-occupational and unknown) and by presence or absence of fibrosis on CT, in order to undertake hypothesis testing.
RESULTS: Cases were occupational (n = 50), non-occupational (n = 56) or cryptogenic (n = 100) in aetiology. The commonest causes were birds = 37 (18%) and MWF = 36 (17%). Other occupational causes included humidifiers and household or commercial waste, but only one case of farmers' lung. Cryptogenic cases were associated with significantly older age, female gender, lower lung function parameters, fewer alveolar lymphocyte counts >20%, and fibrosis on CT; exposure information was missing in 22-33% of cryptogenic cases.
CONCLUSION: MWF is the commonest occupational cause of HP, where workers usually present with more acute/subacute features and less fibrosis on CT; refuse work is an emerging cause. Cryptogenic HP has a fibrotic phenotype, and a full occupational history should be taken, as historical workplace exposures may be relevant. Crown
Copyright © 2019. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Avian protein; Diagnosis; Hypersensitivity pneumonitis; Interstitial lung disease; Metalworking fluid

Year:  2019        PMID: 31295673     DOI: 10.1016/j.rmed.2019.06.026

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  4 in total

Review 1.  [Overview: granulomatous diseases of the lung].

Authors:  Florian Stellmacher; Sven Perner
Journal:  Pathologe       Date:  2021-01-21       Impact factor: 1.011

2.  S1P1 Contributes to Endotoxin-enhanced B-Cell Functions Involved in Hypersensitivity Pneumonitis.

Authors:  Carole-Ann Huppé; Pascale Blais-Lecours; Emilie Bernatchez; Jean-François Lauzon-Joset; Caroline Duchaine; Hugh Rosen; Geneviève Dion; Kelly M McNagny; Marie-Renée Blanchet; Mathieu C Morissette; David Marsolais
Journal:  Am J Respir Cell Mol Biol       Date:  2020-08       Impact factor: 6.914

Review 3.  Sarcoidosis: Pitfalls and Challenging Mimickers.

Authors:  Naureen Narula; Michael Iannuzzi
Journal:  Front Med (Lausanne)       Date:  2021-01-11

4.  Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline.

Authors:  Ganesh Raghu; Martine Remy-Jardin; Christopher J Ryerson; Jeffrey L Myers; Michael Kreuter; Martina Vasakova; Elena Bargagli; Jonathan H Chung; Bridget F Collins; Elisabeth Bendstrup; Hassan A Chami; Abigail T Chua; Tamera J Corte; Jean-Charles Dalphin; Sonye K Danoff; Javier Diaz-Mendoza; Abhijit Duggal; Ryoko Egashira; Thomas Ewing; Mridu Gulati; Yoshikazu Inoue; Alex R Jenkins; Kerri A Johannson; Takeshi Johkoh; Maximiliano Tamae-Kakazu; Masanori Kitaichi; Shandra L Knight; Dirk Koschel; David J Lederer; Yolanda Mageto; Lisa A Maier; Carlos Matiz; Ferran Morell; Andrew G Nicholson; Setu Patolia; Carlos A Pereira; Elisabetta A Renzoni; Margaret L Salisbury; Moises Selman; Simon L F Walsh; Wim A Wuyts; Kevin C Wilson
Journal:  Am J Respir Crit Care Med       Date:  2020-08-01       Impact factor: 30.528

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.